Biomarker-Targeted Therapies in Non–Small Cell Lung Cancer: Current Status and Perspectives

Non-small-cell lung cancer (NSCLC) is one of the most common malignancies and the leading causes of cancer-related death worldwide. Despite many therapeutic advances in the past decade, NSCLC remains an incurable disease for the majority of patients. Molecular targeted therapies and immunotherapies...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Haiyang, Zhang, Jun, Qin, Chao, Yan, Hang, Liu, Tao, Hu, Haiyang, Tang, Shengjie, Tang, Shoujun, Zhou, Haining
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600447/
https://www.ncbi.nlm.nih.gov/pubmed/36291069
http://dx.doi.org/10.3390/cells11203200
_version_ 1784816844582944768
author Guo, Haiyang
Zhang, Jun
Qin, Chao
Yan, Hang
Liu, Tao
Hu, Haiyang
Tang, Shengjie
Tang, Shoujun
Zhou, Haining
author_facet Guo, Haiyang
Zhang, Jun
Qin, Chao
Yan, Hang
Liu, Tao
Hu, Haiyang
Tang, Shengjie
Tang, Shoujun
Zhou, Haining
author_sort Guo, Haiyang
collection PubMed
description Non-small-cell lung cancer (NSCLC) is one of the most common malignancies and the leading causes of cancer-related death worldwide. Despite many therapeutic advances in the past decade, NSCLC remains an incurable disease for the majority of patients. Molecular targeted therapies and immunotherapies have significantly improved the prognosis of NSCLC. However, the vast majority of advanced NSCLC develop resistance to current therapies and eventually progress. In this review, we discuss current and potential therapies for NSCLC, focusing on targeted therapies and immunotherapies. We highlight the future role of metabolic therapies and combination therapies in NSCLC.
format Online
Article
Text
id pubmed-9600447
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96004472022-10-27 Biomarker-Targeted Therapies in Non–Small Cell Lung Cancer: Current Status and Perspectives Guo, Haiyang Zhang, Jun Qin, Chao Yan, Hang Liu, Tao Hu, Haiyang Tang, Shengjie Tang, Shoujun Zhou, Haining Cells Review Non-small-cell lung cancer (NSCLC) is one of the most common malignancies and the leading causes of cancer-related death worldwide. Despite many therapeutic advances in the past decade, NSCLC remains an incurable disease for the majority of patients. Molecular targeted therapies and immunotherapies have significantly improved the prognosis of NSCLC. However, the vast majority of advanced NSCLC develop resistance to current therapies and eventually progress. In this review, we discuss current and potential therapies for NSCLC, focusing on targeted therapies and immunotherapies. We highlight the future role of metabolic therapies and combination therapies in NSCLC. MDPI 2022-10-12 /pmc/articles/PMC9600447/ /pubmed/36291069 http://dx.doi.org/10.3390/cells11203200 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Guo, Haiyang
Zhang, Jun
Qin, Chao
Yan, Hang
Liu, Tao
Hu, Haiyang
Tang, Shengjie
Tang, Shoujun
Zhou, Haining
Biomarker-Targeted Therapies in Non–Small Cell Lung Cancer: Current Status and Perspectives
title Biomarker-Targeted Therapies in Non–Small Cell Lung Cancer: Current Status and Perspectives
title_full Biomarker-Targeted Therapies in Non–Small Cell Lung Cancer: Current Status and Perspectives
title_fullStr Biomarker-Targeted Therapies in Non–Small Cell Lung Cancer: Current Status and Perspectives
title_full_unstemmed Biomarker-Targeted Therapies in Non–Small Cell Lung Cancer: Current Status and Perspectives
title_short Biomarker-Targeted Therapies in Non–Small Cell Lung Cancer: Current Status and Perspectives
title_sort biomarker-targeted therapies in non–small cell lung cancer: current status and perspectives
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600447/
https://www.ncbi.nlm.nih.gov/pubmed/36291069
http://dx.doi.org/10.3390/cells11203200
work_keys_str_mv AT guohaiyang biomarkertargetedtherapiesinnonsmallcelllungcancercurrentstatusandperspectives
AT zhangjun biomarkertargetedtherapiesinnonsmallcelllungcancercurrentstatusandperspectives
AT qinchao biomarkertargetedtherapiesinnonsmallcelllungcancercurrentstatusandperspectives
AT yanhang biomarkertargetedtherapiesinnonsmallcelllungcancercurrentstatusandperspectives
AT liutao biomarkertargetedtherapiesinnonsmallcelllungcancercurrentstatusandperspectives
AT huhaiyang biomarkertargetedtherapiesinnonsmallcelllungcancercurrentstatusandperspectives
AT tangshengjie biomarkertargetedtherapiesinnonsmallcelllungcancercurrentstatusandperspectives
AT tangshoujun biomarkertargetedtherapiesinnonsmallcelllungcancercurrentstatusandperspectives
AT zhouhaining biomarkertargetedtherapiesinnonsmallcelllungcancercurrentstatusandperspectives

Ejemplares similares